Dare Bioscience/$DARE
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Dare Bioscience
Dare Bioscience Inc is a biopharmaceutical company committed to advancing products for women's health. The company identifies, develops, and brings to market a diverse portfolio of differentiated therapies that prioritize women's health and well-being, expand treatment options, and improve outcomes, in the areas of contraception, fertility, and vaginal and sexual health. The company's first product, XACIATO is a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in females 12 years of age and older. The company's portfolio includes two product candidates in clinical development namely, Ovaprene and Sildenafil Cream. It has one operating segment, women's health.
Ticker
$DARE
Sector
Primary listing
Industry
Pharmaceuticals
Headquarters
Employees
22
ISIN
US23666P2002
Website
Dare Bioscience Metrics
BasicAdvanced
$23M
-
-$0.20
1.20
-
Price and volume
Market cap
$23M
Beta
1.2
52-week high
$5.03
52-week low
$2.56
Average daily volume
32K
Financial strength
Current ratio
0.558
Quick ratio
0.493
Long term debt to equity
-13.104
Total debt to equity
-37.356
Profitability
EBITDA (TTM)
-21.82
Gross margin (TTM)
-63,950.77%
Net profit margin (TTM)
-6,470.92%
Operating margin (TTM)
-84,981.08%
Management effectiveness
Return on assets (TTM)
-86.98%
Return on equity (TTM)
16.31%
Valuation
Price to revenue (TTM)
872.305
Price to book
-2.43
Price to tangible book (TTM)
-2.43
Price to free cash flow (TTM)
3.758
Free cash flow yield (TTM)
26.61%
Free cash flow per share (TTM)
69.98%
Growth
Revenue change (TTM)
-99.08%
Earnings per share change (TTM)
-94.87%
3-year earnings per share growth (CAGR)
-69.27%
What the Analysts think about Dare Bioscience
Analyst ratings (Buy, Hold, Sell) for Dare Bioscience stock.
Dare Bioscience Financial Performance
Revenues and expenses
Dare Bioscience Earnings Performance
Company profitability
Dare Bioscience News
AllArticlesVideos
Daré Bioscience Announces Adjournment of Annual Meeting of Stockholders
GlobeNewsWire·2 weeks ago
Daré Bioscience Reports First Quarter 2025 Financial Results and Provides Company Update
GlobeNewsWire·1 month ago
Daré Bioscience Reports Full Year 2024 Financial Results and Provides Company Update
GlobeNewsWire·3 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Dare Bioscience stock?
Dare Bioscience (DARE) has a market cap of $23M as of June 28, 2025.
What is the P/E ratio for Dare Bioscience stock?
The price to earnings (P/E) ratio for Dare Bioscience (DARE) stock is 0 as of June 28, 2025.
Does Dare Bioscience stock pay dividends?
No, Dare Bioscience (DARE) stock does not pay dividends to its shareholders as of June 28, 2025.
When is the next Dare Bioscience dividend payment date?
Dare Bioscience (DARE) stock does not pay dividends to its shareholders.
What is the beta indicator for Dare Bioscience?
Dare Bioscience (DARE) has a beta rating of 1.2. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.